___

• 1. Atbinici H, Sipahioglu S, Aksoy N, Baykara I, Isikan UE. Effects of salmon calcitonin treatment on serum and synovial fluid bone formation and resorption markers in osteoporosis patients. Acta Orthop Traumatol Turc. 2015;49:160e165.
• 2. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142: 5050e5055.
• 3. Crotti TN, Smith MD, Findlay DM, et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials. 2004;25: 565e573.
• 4. Bettica P, Cline G, Hart DJ, Meyer J, Spector TD. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum. 2002;46:3178e3184.
• 5. Straburzynska-Lupa A, Nowak A, Romanowski W, Korman P, Pilaczy
  nska-
  Szcze
  sniak Ł. A study of the link between bone turnover markers and bone mineral density with inflammation and body mass in postmenopausal women with active rheumatoid arthritis. J Bone Miner Metab. 2013;31:169e176.
• 6. Demircan K, Akyol S, Armutcu F. A multi-functional gene family from arthritis to cancer: a disintegrin-like metalloproteinase with thrombospondin type-1 motif (ADAMTS). J Clin Anal Med. 2013;4:429e434.
• 7. Lekkerkerker F, Kanis JA, Alsayed N, et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int. 2007 Oct;18(10):1311e1317.